Joël Nargeot

Title: Joël Nargeot: Innovator in Apoptosis and Analgesic Research

Introduction

Joël Nargeot is a prominent inventor based in Montpellier, France. He has made significant contributions to the fields of apoptosis and analgesic research. With a total of 2 patents, his work focuses on innovative solutions for medical applications.

Latest Patents

Nargeot's latest patents include groundbreaking inventions. One patent is titled "Inhibitors of apoptosis and uses thereof." This invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, particularly apoptosis mediated by the Fas receptor. The invention also encompasses derivatives of these anti-apoptotic fragments, conjugates, and pharmaceutical compositions for treating diseases associated with apoptosis.

Another notable patent is "Identification of novel antagonist toxins of T-type calcium channel for analgesic purposes." This patent describes a peptide with the sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or its derivatives, along with nucleic acids coding for this peptide. The use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels is also highlighted, particularly for developing analgesic drugs.

Career Highlights

Throughout his career, Joël Nargeot has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and Université Montpellier 2-Sciences et Techniques. His research has significantly advanced the understanding of apoptosis and pain management.

Collaborations

Nargeot has collaborated with notable colleagues, including Michel Lazdunski and Prisca Boisguerin. Their joint efforts have contributed to the success of various research projects and innovations.

Conclusion

Joël Nargeot's contributions to the fields of apoptosis and analgesic research are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science.